Sugi Predict

Sugi Predict / Targets / RTN3

RTN3

Reticulon-3 · O95197 · RTN3 on Sugi Atlas →

0 patent compounds predicted against RTN3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RTN3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) PHASE1/PHASE2RECRUITING
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) PHASE2COMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
sCD163 in ALS Patients nanCOMPLETED
Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases nanCOMPLETED
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models nanCOMPLETED
Implementation of Molecular Diagnostic Pathways nanUNKNOWN
Characteristics of Idiopathic Familial Voice Disorders nanCOMPLETED
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis nanRECRUITING
Advancing Neurogenetic Diagnoses Through Long-Read Sequencing nanNOT_YET_RECRUITING
Molecular and Genetic Studies of Congenital Myopathies nanRECRUITING
Nerve Ultrasound in Acquired and Genetic Sensory Neuronopathies nanNOT_YET_RECRUITING
Identification of New FTLD Genes nanUNKNOWN
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD nanENROLLING_BY_INVITATION
B3 for NMD: Bench to Bedside and Back nanENROLLING_BY_INVITATION
Biomarker for Gaucher Disease: BioGaucher (BioGaucher) nanWITHDRAWN
Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae nanACTIVE_NOT_RECRUITING
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program nanCOMPLETED
Genetics of Familial and Sporadic ALS nanCOMPLETED
Neuromuscular Transmission in Amyotrophic Lateral Sclerosis nanCOMPLETED
Molecular Analysis of Patients With Neuromuscular Disease nanRECRUITING
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis nanCOMPLETED
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) nanCOMPLETED
Biomarker Research in Inherited Movement Disorders nanRECRUITING
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others nanRECRUITING
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RTN3 binder may also engage these)

ProteinNameSimilarity
Q99P72 — 0.997 Q99P72 →
Q6RJR6 — 0.997 Q6RJR6 →
Q9ES97 — 0.996 Q9ES97 →
RTN4 Reticulon-4 0.994 landscape →
Q9JK11 — 0.994 Q9JK11 →
O94854 — 0.992 O94854 →
Q6NS59 — 0.991 Q6NS59 →
A7MC64 — 0.991 A7MC64 →
Q5DTW7 — 0.991 Q5DTW7 →
E1BC15 — 0.990 E1BC15 →
ASH1L Histone-lysine N-methyltransferase ASH1L 0.990 landscape →
Q9Y2F5 — 0.990 Q9Y2F5 →
P56716 — 0.989 P56716 →
MAP3K19 Mitogen-activated protein kinase kinase kinase 19 0.989 landscape →
Q3V089 — 0.989 Q3V089 →
Q9P2D6 — 0.989 Q9P2D6 →
Q95J40 — 0.989 Q95J40 →
Q9ULD2 — 0.989 Q9ULD2 →
A2AEY4 — 0.989 A2AEY4 →
A1L2H3 — 0.988 A1L2H3 →
MKI67 Proliferation marker protein Ki-67 0.988 landscape →
Q8K0T0 — 0.988 Q8K0T0 →
A4IGL8 — 0.988 A4IGL8 →
Q9UKL3 — 0.988 Q9UKL3 →
Q80U44 — 0.988 Q80U44 →
F6ULY3 — 0.988 F6ULY3 →
Q5VWN6 — 0.988 Q5VWN6 →
Q7Z5L2 — 0.988 Q7Z5L2 →
Q8N7Z5 — 0.988 Q8N7Z5 →
Q8MJ05 — 0.988 Q8MJ05 →